Polyrizon Ltd. has announced new preclinical data demonstrating that its proprietary intranasal naloxone hydrogel exhibits significantly greater mucoadhesion compared to an existing marketed intranasal naloxone spray. The study, conducted using an ex-vivo rabbit nasal mucosa model, found that the hydrogel formulation maintained higher levels of a fluorescence marker after repeated washing, indicating stronger and more durable retention on the nasal tissue. These results, which have already been presented, suggest that Polyrizon's Trap and Target (T&T) hydrogel technology may enhance bioavailability and reliability for opioid overdose reversal.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Polyrizon Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9596118-en) on December 03, 2025, and is solely responsible for the information contained therein.